Fresenius Kabi Compounding LLC dba Fagron Sterile Services, Canton, MA
Is Fresenius Kabi Compounding LLC dba Fagron Sterile Services an FDA-registered 503B outsourcing facility?
Yes. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names Fresenius Kabi Compounding LLC dba Fagron Sterile Services in Canton, MA, first registered Apr 21, 2017 and most recently registered Nov 22, 2025. FDA lists its last inspection as Nov 5, 2025, with a Form FDA 483 issued; FDA lists the action on that inspection as “Warning Letter Issued 5/12/2026”.
FDA registers outsourcing facilities under section 503B; state boards of pharmacy issue pharmacy licenses separately. FDA’s list does not say which drugs a facility makes.
- Location on FDA’s list
- Canton, MA
- Initial registration
- Apr 21, 2017
- Most recent registration
- Nov 22, 2025
- Last inspection
- Nov 5, 2025
- Form 483 issued at last inspection
- Yes
- Recall after last inspection
- No
- Action on last inspection
- Warning Letter Issued 5/12/2026
- Intends to compound sterile drugs from bulk substances
- Yes
FDA inspections and actions on record
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this facility as Fresenius Kabi Compounding, LLC, Canton, MA, a 503B facility, with 4 listed actions, including 2 Form 483s (2020 to 2025).
| Document | |||
|---|---|---|---|
| Nov 5, 2025 | Form 483 | 483 Issued 11/05/2025 | fda.gov |
| Aug 11, 2023 | FMD-145 letter | FMD-145 Letter Issued 08/11/2023 | Not linked by FDA |
| Mar 6, 2023 | Form 483 | 483 Issued 03/06/2023 | fda.gov |
| Apr 22, 2020 | FMD-145 letter | FMD-145 Letter Issued 04/22/2020 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
Matched to the 503B list by city, state and the exact legal name with the same legal ending. Check the heading above against the facility you are looking for.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Fresenius Kabi Compounding, LLC, Canton, MA (FEI number 3013438665), matched to this page by exact name, city and state. It lists 3 inspections: 1 OAI, 2 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Nov 5, 2025 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3013438665 | 1290368 |
| Mar 6, 2023 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3013438665 | 1201601 |
| Dec 4, 2018 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3013438665 | 1074214 |
Form 483s FDA has published for this site
- Nov 5, 2025: Form 483 to Fresenius Kabi Compounding, LLC, published Jan 20, 2026. fda.gov
- Mar 6, 2023: Form 483 to Fresenius Kabi Compounding, LLC, published Jul 13, 2023. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 9 numbered observations in all, across 2 inspections ending Mar 6, 2023 to Nov 5, 2025. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Oct 9, 2025 to Nov 5, 2025: 7 observations
- Firm on the cover
- Fresenius Kabi Compounding, LLC, 20 Dan Rd, Canton, MA 02021-2809
- FEI number
- 3013438665
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 109 Holt on Street Winchester, MA 01890
- Matched to this page by
- FEI number on the cover; linked from actions page, 503B list, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Specifically, your firm detected defects in <Redacted B4> infusion and <Redacted B4> injection ports on some of the IV bag container closures of your compounded sterile drug product CSP's. Defects include the port not being properly fused to the IV bag and may lead to leaking, port falling off the IV bag with minimal manipulation, or other container closure integrity issues. These defects affect units in multiple lots of multiple products, for example:
Vancomycin HCl 1.25 grams added to 250 mL 0.9% Sodium Chloride Injection USP IV Bag, Preservative Free, Lot C274-000048802, MFG 10/6/2025, EXP 4/4/2026
Phenylephrine HCl 20 mg added to 250 mL (80 mcg/mL) 0.9% Sodium Chloride Injection, Solution USP IV Bag, Lot C274-000048505, MFG 9/22/2025, EXP 3/21/2026 ...
Observation 2
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.
Specifically,
a. Multiple examples were observed in which procedures regarding operator conduct were not established or followed:
1. During vancomycin reconstitution operations on 10/17/25, multiple instances were observed in which operator movements inside ISO <Redacted B4> laminar flow hoods obstructed first-pass air to uncapped vials of <Redacted B4> vancomycin. For example, during vial reconstitution for production of Vancomycin HCl 1.75g Bag lot C274-000048979 in Laminar Flow Hood <Redacted B4>, we observed an operator's aims pass between first-pass air and pre-and post-dilution vials. This occurred while the operator was obtaining undiluted vials from the rack, returning reconstituted vials to the rack, and replacing the diluent bag. In the same operation, five diluent bags were hung above the racks of undiluted vials on one hook. Your firm lacks data to demonstrate that first-pass air is not obstiucted by the expanded silhouette of five diluent bags. ...
Observation 3
The responsibilities and procedures applicable to the quality control unit are not fully followed.
Specifically, your firm has been using drug products known to be defective ( defective ports on <Redacted B4> IV bags) for compounding since 10/2024. Among the <Redacted B4> batches of CSP's made at least in part from the initially identified defective IV bag lot (lot 23SU10008),r batches were fully distributed to customers. While DEV-2024-1626 states that this defect is highly detectable during visual inspection, your fnm opened Issue-2024-0039 on 7/26/2024 for operators failing visual inspection requalification for IV bags.
l
SOP FSSBOS-SOP-0018 " Visual inspection of Compounded Sterile Products" indicates that the allowable defect limit for critical port defects <Redacted B4> yet your firm released lots with port defects above <Redacted B4> such as vancomycin HCl <Redacted B4> 1 gram added to 250 mL 0.9% Sodium Chloride Injection USP IV Bag, Preservative Free lot C274-000040486 on 10/2/2024 with a port defect rate of 14.9% of the batch.
As of 10/25/2025, your fnm identified that approximately >r<41'. ...
Observation 4
Your examination and testing of samples did not assure that the drug product and in-process material conformed to specifications.
Specifically, on 10/10/2025, your firm's visual inspection hoods including EOOl 13.00 in Room <Redacted B4> were observed to contain dust-like particles on the <Redacted B4> (visual inspection backgrounds. Your firm also lacks a written procedure for cleaning of <Redacted B4> surfaces in the visual inspection hoods including backgrounds. On 10/16/2025, during visual inspection of lot C274-000048970 of oxytocin D USP units added to 500 mL 0.9% Sodium Chloride Injection, USP IV Bag, we observed dust-like pa1ticles on the <Redacted B4> backgrounds in the visual inspection hoods that the inspectors were using.
Observation 5
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically, active viable air sampling was not performed at a time representative of production operations. The firm performs active viable air sampling after operators folly conclude a stage of dru g production , i.e. , reconstitution , pooling , o r filling , i n accordanc e wit h th e firm 's environment al monitori ng procedure s. Additionall y, settli ng plat es in the <
Re
dac ted B4 > ho ods are not always pl ac ed in a location representative of production acti vities, as obse rved on 10 /17/25 during vial reconsti tuti on for Vancomycin HCl 1.75g Bag <Redacted B4> lot C274-000048979 in Hood <Re
da
cte d B4> and pool ing of Oxytocin <Redact ed B4> Units Bag lot C274-000048976 in Hood <Redacted B4> as well as on 1 0/10/25 during filling of Lidocaine 2% 5mL Syringe lot C274-000048894 in Hood <Redacted B4>
Observation 6
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.
AMENDMENT 1
Specifically,
a. On 10/10/25, a brown, rust-like residue was observed on the <Redacted B4> of multiple tables and laminar flow hoods, including all 4 tables and all <Redacted B4> hoods in ISO <Redacted B4> Room <Redacted B4> tables and <Redacted B4> hoods in ISO <Redacted B4> Room <Redacted B4> and a table in ISO Room <Redacted B4>. Your procedure governing laminar flow hoods requires operators to clean the <Redacted B4> with a de-rouging agent during <Redacted B4> cleanings <Redacted B4> departures are observed to communicate <Redacted B4> with management if residue cannot the removed. Room <Redacted B4> and Room <Redacted B4> 1 each contain <Redacted B4> ISO laminar flow hoods for production of all firm drug products. Room <Redacted B4> is used as the <Redacted B4> exit for the <Redacted B4> and for clean staging/storage of materials going into Room <Redacted B4> and Room <Redacted B4> for drug production. ...
Observation 7
Buildings used in the manufacturing and processing of a drug product are not maintained in a good state of repair.
Specifically,
AM ENDMENT 1
b. On 10/21/25, paint chipping was observed in <Re da
ct ed B4 > ' R oom fell on the door leading to < Redacted B4> Room <Redacted B4>. Your firm performs vial reconstitution and pooling for vancom
yc in drug products in Room <Redacted B4>
c. On 10/10/25, a divot in the floor was observed at the foot of Laminar Flow Hood <Redacted B4> in Room <Redacted B4>
Inspection Jan 30, 2023 to Mar 6, 2023: 2 observations
- Firm on the cover
- Fresenius Kabi Compounding, LLC, 20 Dan Rd, Canton, MA 02021-2809
- FEI number
- 3013438665
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- One Montvale Avenue Stoneham, M A 0 2180
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.
Specifically, on 01/31/2023, production operators were observed performing preproduction cleaning of the interior of the ISO 5 <Redacted B4> HLFs located in ISO 7 Room 139. During the cleaning operations, multiple oeerators were observed leaning their bodies inside the ISO 5 <Redacted B4> LFHs in order to clean the interior of the <Redacted B4> LFHs. By cleaning inside the ISO 5 <Readacted B4> LFHs, the operators blocked the path of the unidirectional airflow inside the <Redacted B4> LFHs immediately prior to performing production operations. Operators then manufactured Rocuronium 50mg per 5mL Syrinri, Lot # <Redacted B4> LFH # <Redacted B4>; Phenylephrine HCl 20mg added to 250mL Bag, L~ <Redacted B4> in <Redacted B4> LFH <Redacted B4> ; Vancomycin HCl 2g added to 500mL Bag, Lot# <Redacted B4> LFH <Redacted B4>; and Norepinephrine 4mg added to 250mL Bag, Lot # <Redacted B4> in LFH <Redacted B4> .
Observation 2
The accuracy, sensitivity, specificity and reproducibility of test methods have not been established.
Specifically, the USP <71> method suitability tests performed for your injectable Vancomycin drug products failed to recover Bacillus subtilis demonstrating that the <Redacted B4> were not adequately neutralizing the antibiotic in order to detect all potential Inicrobial contamination. Between June 11, 2021, and January 30, 2023, your firm used USP <71> to perform sterility testing on approximately <Redacted B4> batches of your injectable Vancomycin drug products that were distributed for use in treating patients.
GLP-1 records in this index
No FDA warning letter or recall report naming a GLP-1 drug in this index, as of Nov 15, 2026, is addressed to this facility’s exact legal name (Fresenius Kabi Compounding LLC dba Fagron Sterile Services). That is not a finding beyond this index’s search.
The Fresenius Kabi Compounding LLC dba Fagron Sterile Services pharmacy page answers whether it has had a state board action or FDA letter, from the same FDA lists.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA Registered Outsourcing Facilities (503B)
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
Records last pulled Nov 15, 2026. Every entry links to the original public record.